167 related articles for article (PubMed ID: 30242098)
21. Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National Cancer Data Base.
Jegadeesh N; Liu Y; Gillespie T; Fernandez F; Ramalingam S; Mikell J; Lipscomb J; Curran WJ; Higgins KA
Clin Lung Cancer; 2016 Sep; 17(5):398-405. PubMed ID: 26936682
[TBL] [Abstract][Full Text] [Related]
22. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Yom SS; Liao Z; Liu HH; Tucker SL; Hu CS; Wei X; Wang X; Wang S; Mohan R; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):94-102. PubMed ID: 17321067
[TBL] [Abstract][Full Text] [Related]
23. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
[TBL] [Abstract][Full Text] [Related]
24. [Technical advancement improves survival in patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving definitive radiotherapy].
Wang JB; Jiang W; Ji Z; Cao JZ; Liu LP; Men Y; Xu C; Wang XZ; Hui ZG; Liang J; Lyu JM; Zhou ZM; Xiao ZF; Feng QF; Chen DF; Zhang HX; Yin WB; Wang LH
Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):607-14. PubMed ID: 27531481
[TBL] [Abstract][Full Text] [Related]
25. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
[TBL] [Abstract][Full Text] [Related]
26. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
[TBL] [Abstract][Full Text] [Related]
27. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.
Minn AY; Hsu A; La T; Kunz P; Fisher GA; Ford JM; Norton JA; Visser B; Goodman KA; Koong AC; Chang DT
Cancer; 2010 Aug; 116(16):3943-52. PubMed ID: 20564136
[TBL] [Abstract][Full Text] [Related]
28. The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States.
Vargo JA; Patel A; Glaser SM; Balasubramani GK; Farah RJ; Marks SM; Beriwal S
Cancer; 2017 Aug; 123(16):3176-3185. PubMed ID: 28380259
[TBL] [Abstract][Full Text] [Related]
29. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
[TBL] [Abstract][Full Text] [Related]
30. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).
Deng XW; Wu JX; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Dong M; Qi SN; Yang Y; Li YX
Radiother Oncol; 2018 Oct; 129(1):3-9. PubMed ID: 29739712
[TBL] [Abstract][Full Text] [Related]
31. IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma : Survival outcome in a Korean multi-institutional retrospective study (KROG 11-06).
Moon SH; Cho KH; Lee CG; Keum KC; Kim YS; Wu HG; Kim JH; Ahn YC; Oh D; Lee JH
Strahlenther Onkol; 2016 Jun; 192(6):377-85. PubMed ID: 26972085
[TBL] [Abstract][Full Text] [Related]
32. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.
Qi SN; Yang Y; Zhang YJ; Huang HQ; Wang Y; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Song YQ; Zhu J; Hu C; Li YX
Am J Hematol; 2020 Sep; 95(9):1047-1056. PubMed ID: 32449800
[TBL] [Abstract][Full Text] [Related]
33. Phase 2 Clinical Trial of Simultaneous Boost Intensity Modulated Radiation Therapy With 3 Dose Gradients in Patients With Stage I-II Nasal Type Natural Killer/T-Cell Lymphoma: Long-Term Outcomes of Survival and Quality of Life.
Niu S; Li Y; Shao H; Hu J; Wang J; Wang H; Zhang Y
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):770-780. PubMed ID: 37939733
[TBL] [Abstract][Full Text] [Related]
34. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer.
Goto Y; Nakamura A; Ashida R; Sakanaka K; Itasaka S; Shibuya K; Matsumoto S; Kanai M; Isoda H; Masui T; Kodama Y; Takaori K; Hiraoka M; Mizowaki T
Radiat Oncol; 2018 Jun; 13(1):118. PubMed ID: 29940984
[TBL] [Abstract][Full Text] [Related]
36. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
[TBL] [Abstract][Full Text] [Related]
37. Effect of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy on clinical outcomes in patients with glioblastoma multiforme.
Chen YD; Feng J; Fang T; Yang M; Qiu XG; Jiang T
Chin Med J (Engl); 2013 Jun; 126(12):2320-4. PubMed ID: 23786946
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer.
Mok G; Gauthier I; Jiang H; Huang SH; Chan K; Witterick IJ; O'Sullivan B; Waldron JN; Bayley AJ; Cho BC; Cummings BJ; Dawson LA; Hope AJ; Kim JJ; Ringash J
Head Neck; 2015 May; 37(5):655-61. PubMed ID: 24590756
[TBL] [Abstract][Full Text] [Related]
39. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
40. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
